london euretina
retina race

Intravitreal ranibizumab versus aflibercept for choroidal neovascularization associated with pathologic myopia

Session Details

Session Title: Vitreoretinal Surgery II

Session Date/Time: Friday 18/09/2015 | 08:00-10:00

Paper Time: 08:48

Venue: Calliope

First Author: : A.Korol UKRAINE

Co Author(s): :    T. Kustryn   O. Zadorozhnyy   N. Pasyechnikova        

Abstract Details

PURPOSE:to assess efficacy of intravitreal ranibizumab compared with aflibercept in treatment of choroidal neovascularization associated with pathologic myopia.

Setting:

State Institution “The Filatov`s Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine”

Methods:

94 patients (96 eyes) with choroidal neovascularization (CNV) associated with pathologic myopia (PM) were observed. The primary outcome was the difference in mean changes in best-corrected visual acuity (BCVA) at Month 12. Secondary outcomes included change in central retinal thickness (CRT) in the foveal area on OCT from baseline at Month 12, quantity of intravitreal injections.

Results:

65 eyes received either 0.5 mg intravitreal ranibizumab, 31 eyes received 2.0 mg intravitreal aflibercept. The mean decimal BCVA at baseline in ranibizumab and aflibercept groups was 0.2 (0.1) in each group(p=0.6). At Month 12, the mean BCVA was 0.4 (0.2) (p=0.001) in ranibizumab group and 0.38 (0.2) (p=0.001) in aflibercept group. The difference between the mean decimal BCVA of the treated groups (ranibizumab–aflibercept) was no significant (p=0.2). The baseline mean CRT in ranibizumab was 314 (79) µm and in aflibercept group was 285 (62) µm (p=0.01). At Month 12, the mean CRT were 243 (31) µm in ranibizumab group (p=0.001) and 227 (39) µm in aflibercept group (p=0.01), with significant difference between two groups (p=0.04). The mean numbers of ranibizumab and aflibercept injections were 2.3 (0.9) and 2.6 (1.0), respectively (p=0.15).

Conclusions:

this study demonstrated similar significant gain in visual acuity in eyes with CNV associated with PM treated with either ranibizumab or aflibercept, with no significant difference in quantity of intravitreal injections.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy